Navigation Links
ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction
Date:2/23/2011

MARLBOROUGH, Mass., Feb. 23, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that it has been issued a patent on its "single-blastomere" technique.  Patent Number 7,893,315 broadly covers ACT's proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.  

"Of the more than 150 patents and patent applications related to stem cell therapy and regenerative medicine that ACT owns or licenses, this patent on our single-blastomere technology is one of the most significant," stated Gary Rabin, ACT's interim chairman and CEO.  "It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology.  We are currently developing a collaboration for creating banks of these cells using our proprietary technique with the United Kingdom's Roslin Cells.  This is an example of the type of potentially revenue-generating future partnership that we think this IP (intellectual property) protection could help facilitate."

The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo's developmental potential.  The stem cells generated using this approach are healthy, completely normal, and differentiate into all the cell types of the human body, including insulin-producing cells, blood cells, beating heart cells, cartilage, and other cell types of therapeutic importance.  The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world.  ACT's "embryo-safe" technique has been published in been peer-reviewed journals such as Nature and Cell Stem Cell.

Robert Lanza, M.D., chief scientific officer of ACT, said, "This patent issuance represents recognition of the innovation underlying our single-blastomere technology.  In the US alone, over 100 people die every hour from diseases that could potentially benefit from this 'embryo-safe' technique.  Single cells are removed from the embryos, which remain healthy and continue to develop normally at rates consistent with whole (non-biopsied) embryos. Furthermore, this IP protection follows on the issuance of a broad patent relating to ACT's production and therapeutic use of Retinal Pigment Epithelial (RPE) cells in 2010. We are eagerly anticipating the start of the two Phase 1/2 clinical trials in the first half of this year.  Our RPE program uses hESCs derived from a single blastomere, and as such, this source of embryonic stem cells has been subjected to extensive regulatory scrutiny in order to demonstrate their safety and suitability to be used in human patients on a trial basis."

ACT has been issued clearance from the FDA to proceed with two Phase 1/2 clinical trials in the U.S. for its RPE program, including a Phase 1/2 trial in  patients with dry age-related macular degeneration.

About Advanced Cell Technology, Inc.Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking StatementsStatements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009.  Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. Contact:Investors:CEOcast, Inc., James Young, 212-732-4300Press:ACT Corporate Communications, Bill Douglass, 646-450-3615or:Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292
'/>"/>

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Northwest Secures US$1.0 Million Debt Financing
5. Transave, Inc. Secures $12.5 Million in New Financing
6. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
7. Northwest Secures US$1.65 Million Debt Financing
8. Queens secures £25m for UKs cyber-safety
9. Queens secures £25M for UKs cyber safety
10. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
11. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Today, the South Davis ... Advanced Biological Nutrient Recovery (ABNRâ„¢) technology at its 4,000,000 gallon per day South ... to sustainably meet current and future nutrient discharge regulations. The ABNR platform, which ...
(Date:5/24/2017)... Ebola resurfaces in the Democratic Republic of Congo ... reported, a new analysis of the Ebola gene polymerase Replikin ... 2014 and 2017 outbreaks of the disease.  ... the 2014 outbreak. An analysis of the latest data showed ... which again precedes the current outbreak in the DRC. Sequence ...
(Date:5/23/2017)... ... 2017 , ... Genedata, a leading provider of advanced software ... a strong presence at Bio-IT World Conference & Expo 2017 in Boston, MA. ... all attendees to view posters on the entire range of Genedata software ...
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq Technology, ... announced a facility expansion to accommodate its rapid growth. , The renovations at ... and renovation of the existing areas. The expansion includes, a state-of-the-art engineering facility, ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
Breaking Biology News(10 mins):